{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:24:20Z","timestamp":1791645860248,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate 10-year outcome of infliximab (IFX) treatment for uveitis in Beh\u00e7et disease (BD) patients using a standardized follow-up protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective longitudinal cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>140 BD uveitis patients treated with IFX enrolled in our previous study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medical records were reviewed for demographic information, duration of IFX treatment, number of ocular attacks before IFX initiation, best corrected visual acuity (VA) at baseline and 1, 2, 3, 4, 5, and 10 years after IFX initiation, uveitis recurrence after IFX initiation and main anatomical site, concomitant therapies, and adverse events (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>10-year IFX continuation rate and change in LogMAR VA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 140 BD patients, 106 (75.7%) continued IFX treatment for 10 years. LogMAR VA improved gradually after initiation of IFX, and the improvement reached statistical significance from 2 years of treatment. Thereafter, significant improvement compared with baseline was maintained until 10 years, despite a slight deterioration of logMAR VA from 5 years. However, eyes with worse baseline decimal VA &amp;lt; 0.1 showed no significant improvement from baseline to 10 years. Uveitis recurred after IFX initiation in 50 patients (recurrence group) and did not recur in 56 (non-recurrence group). Ocular attacks\/year before IFX initiation was significantly higher in the recurrence group (2.82 \u00b1 3.81) than in the non-recurrence group (1.84 \u00b1 1.78). In the recurrence group, uveitis recurred within 1 year in 58% and within 2 years in 74%. Seventeen patients (34%) had recurrent anterior uveitis, 17 (34%) had posterior uveitis, and 16 (32%) had panuveitis, with no significant difference in VA outcome. In addition, logMAR VA at 10 years did not differ between the recurrence and non-recurrence groups. AEs occurred among 43 patients (30.7%), and 24 (17.1%) resulted in IFX discontinuation before 10 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Among BD patients with uveitis who initiated IFX, approximately 75% continued treatment for 10 years, and their VA improved significantly and was maintained for 10 years. Uveitis recurred in one-half of the patients, but visual acuity did not differ significantly from the patients without recurrence.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1095423","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T05:11:35Z","timestamp":1674191495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Ten-year follow-up of infliximab treatment for uveitis in Beh\u00e7et disease patients: A multicenter retrospective study"],"prefix":"10.3389","volume":"10","author":[{"given":"Masaru","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Keino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koju","family":"Kamoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Mashimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Ohguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle A.","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00005792-197505000-00001","article-title":"Behcet\u2019s disease. report of 41 cases and a review of the literature.","volume":"54","author":"Chajek","year":"1975","journal-title":"Medicine (Baltimore)."},{"key":"B2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-4362.1984.tb05658.x","article-title":"Behcet\u2019s disease.","volume":"23","author":"Wong","year":"1984","journal-title":"Int J Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/nejm199910213411707","article-title":"Beh\u00e7et\u2019s disease.","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.revmed.2013.10.011","article-title":"[Ocular manifestations in Beh\u00e7et\u2019s disease].","volume":"35","author":"Zeghidi","year":"2014","journal-title":"Rev Med Interne."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","article-title":"Ocular features of Behcet\u2019s disease: an international collaborative study.","volume":"91","author":"Kitaichi","year":"2007","journal-title":"Br J Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ophtha.2003.07.018","article-title":"Comparison of patients with Behcet\u2019s disease in the 1980s and 1990s.","volume":"111","author":"Yoshida","year":"2004","journal-title":"Ophthalmology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Behcet disease: an analysis of 880 patients.","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome.","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease.","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease.","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet\u2019s disease: a comparative 4-week study.","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to behcet\u2019s disease: national multicenter study of 177 cases.","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1793-7","article-title":"Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behcet\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan.","volume":"21","author":"Ohno","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/09273948.2019.1606256","article-title":"Comparison of the treatment results for beh\u00e7et uveitis in patients treated with infliximab and interferon.","volume":"28","author":"Yal\u00e7indag","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B15","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u221a\u00dfet\u2019s disease with refractory uveoretinitis.","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/bjo.2010.194464","article-title":"Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet\u2019s disease on infliximab therapy.","volume":"95","author":"Keino","year":"2011","journal-title":"Br J Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/BTT.S27343","article-title":"Efficacy of infliximab in refractory Behcet\u2019s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients.","volume":"6","author":"Cantini","year":"2012","journal-title":"Biologics."},{"key":"B18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/09273948.2013.779727","article-title":"Long-term clinical outcomes in patients with refractory uveitis associated with Beh\u00e7et disease treated with infliximab.","volume":"21","author":"Al Rashidi","year":"2013","journal-title":"Ocul Immunol Inflamm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2147\/OPTH.S198648","article-title":"Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behcet\u2019s disease.","volume":"13","author":"Katsuyama","year":"2019","journal-title":"Clin Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-018-4092-4","article-title":"Predictors of sustained clinical response in patients with Beh\u00e7et\u2019s disease-related uveitis treated with infliximab and adalimumab.","volume":"37","author":"Fabiani","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet\u2019s disease: a multicenter study.","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet\u2019s disease: an open-label trial.","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in Behcet disease.","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78718-z","article-title":"10-year follow-up of infliximab monotherapy for refractory uveitis in Behcet\u2019s syndrome.","volume":"10","author":"Horiguchi","year":"2020","journal-title":"Sci Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-Year retention rate of infliximab in patients with Beh\u00e7et\u2019s disease-related uveitis.","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1136\/bjophthalmol-2020-316892","article-title":"Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behcet\u2019s disease.","volume":"105","author":"Keino","year":"2021","journal-title":"Br J Ophthalmol."},{"key":"B27","first-page":"66","article-title":"[Revised diagnostic criteria for Behcet\u2019s disease in 1987].","volume":"28","author":"Mizushima","year":"1988","journal-title":"Ryumachi."},{"key":"B28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/bjo.70.8.589","article-title":"Treatment and visual prognosis in Beh\u00e7et\u2019s disease.","volume":"70","author":"Benezra","year":"1986","journal-title":"Br J Ophthalmol."},{"key":"B29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ophtha.2007.04.056","article-title":"Clinical features of chinese patients with Beh\u00e7et\u2019s disease.","volume":"115","author":"Yang","year":"2008","journal-title":"Ophthalmology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ajo.2008.06.019","article-title":"Ocular inflammation in Behcet disease: incidence of ocular complications and of loss of visual acuity.","volume":"146","author":"Kacmaz","year":"2008","journal-title":"Am J Ophthalmol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","article-title":"Safety and efficacy of infliximab therapy in active behcet\u2019s uveitis: an open-label trial.","volume":"29","author":"Al-Rayes","year":"2008","journal-title":"Rheumatol Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/bjo.2009.168856","article-title":"Timing of recurrent uveitis in patients with Behcet\u2019s disease receiving infliximab treatment.","volume":"95","author":"Yamada","year":"2011","journal-title":"Br J Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0162-4","article-title":"Reconstitution of disrupted photoreceptor layer in uveitis associated with Behcet\u2019s disease by infliximab treatment.","volume":"15","author":"Takeuchi","year":"2015","journal-title":"BMC Ophthalmol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3109\/09273948.2012.665124","article-title":"Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behcet\u2019s disease.","volume":"20","author":"Takeuchi","year":"2012","journal-title":"Ocul Immunol Inflamm."},{"key":"B35","first-page":"1078","article-title":"Criteria for diagnosis of Behcet\u2019s disease.","volume":"335","year":"1990","journal-title":"Lancet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/09273948.2017.1351573","article-title":"Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Beh\u00e7et\u2019s disease.","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm."},{"key":"B37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/09273948.2018.1511810","article-title":"The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Beh\u00e7et\u2019s disease.","volume":"28","author":"Fabiani","year":"2020","journal-title":"Ocul Immunol Inflamm."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1095423\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T05:11:41Z","timestamp":1674191501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1095423\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":37,"alternative-id":["10.3389\/fmed.2023.1095423"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1095423","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"article-number":"1095423"}}